The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
127292202 12729220 2 F 20160731 20160912 20160909 20160923 EXP TR-PFIZER INC-2016419833 PFIZER 72.00 YR M Y 70.00000 KG 20160923 OT TR TR

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
127292202 12729220 1 PS VINCRISTINE SULFATE. VINCRISTINE SULFATE 1 Intravenous (not otherwise specified) 2 MG, 1 IN 21 D 71484 2 MG SOLUTION FOR INJECTION
127292202 12729220 2 SS DOXORUBICIN HCL DOXORUBICIN HYDROCHLORIDE 1 Intravenous (not otherwise specified) 90.5 MG, 1 IN 21 D 50467 90.5 MG POWDER FOR SOLUTION FOR INJECTION
127292202 12729220 3 SS LENALIDOMIDE LENALIDOMIDE 1 Oral 15 MG, DAYS 1-14 IN 21 D 0 15 MG
127292202 12729220 4 SS RITUXIMAB RITUXIMAB 1 Intravenous (not otherwise specified) 679 MG, 1 ?N 21 D 0 679 MG
127292202 12729220 5 SS CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE 1 Intravenous (not otherwise specified) 1358 MG, 1 IN 21 D 0 1358 MG
127292202 12729220 6 SS PREDNISONE. PREDNISONE 1 Oral 100 MG, 1-5 IN 21 D 0 100 MG
127292202 12729220 7 C VASTAREL TRIMETAZIDINE DIHYDROCHLORIDE 1 Oral 40 MG, 2X/DAY 0 40 MG BID
127292202 12729220 8 C STABLON TIANEPTINE 1 Oral 25 MG, 2X/DAY 0 25 MG BID
127292202 12729220 9 C LUMEN 2 Intravenous (not otherwise specified) 2/50MG/ML, 3X/DAILY 0 TID
127292202 12729220 10 C KLOROBEN 2 600 ML, 3X/DAY 0 600 ML TID
127292202 12729220 11 C FUNGOSTATIN 2 Oral 100 U/ML, 3X/DAY 0 TID
127292202 12729220 12 C DIMENHYDRINAT DIMENHYDRINATE 1 Intravenous (not otherwise specified) 3/3 MG/ML, 3X/DAY 0 TID
127292202 12729220 13 C ESOMEPRAZOLE MAGNESIUM. ESOMEPRAZOLE MAGNESIUM 1 Intravenous (not otherwise specified) 80 MG, 2X/DAY 0 80 MG BID
127292202 12729220 14 C EMOJECT 2 Intravenous (not otherwise specified) 120 MG, 3X/DAY 0 120 MG TID
127292202 12729220 15 C ENOX /01708202/ 2 Subcutaneous 40 MG, 1X/DAY 0 40 MG QD
127292202 12729220 16 C LANTUS INSULIN GLARGINE 1 Subcutaneous 100 MG/ML, 1X/DAY 0 QD
127292202 12729220 17 C NOVORAPID INSULIN ASPART 1 Subcutaneous 300 MG/ML, 3X/DAY 0 TID
127292202 12729220 18 C TRADOLEX 2 Intravenous (not otherwise specified) 100/2 MG/ML, 3X/DAY 0 TID
127292202 12729220 19 C URIKOLIZ ALLOPURINOL 1 Oral 300 MG, 1X/DAY 0 300 MG QD
127292202 12729220 20 C ATIVAN LORAZEPAM 1 Oral 1 MG, 1X/DAY 0 1 MG QD
127292202 12729220 21 C VALTREX VALACYCLOVIR HYDROCHLORIDE 1 Oral 1 X 0.5 , UNK 0
127292202 12729220 22 C KEMOPRIM 2 Oral 800/160 MG, 2X/DAY 0 BID
127292202 12729220 23 C OSTEVIT D 2 Oral UNK, 1X/DAY 0 QD
127292202 12729220 24 C NORODOL 2 Oral 5/1 MG/ML, 2X5 0
127292202 12729220 25 C TERNAVIR 2 Oral 245 MG, 1X/DAY 0 245 MG QD

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
127292202 12729220 1 Diffuse large B-cell lymphoma
127292202 12729220 2 Diffuse large B-cell lymphoma
127292202 12729220 3 Diffuse large B-cell lymphoma
127292202 12729220 4 Diffuse large B-cell lymphoma
127292202 12729220 5 Diffuse large B-cell lymphoma
127292202 12729220 6 Diffuse large B-cell lymphoma
127292202 12729220 7 Hypertension
127292202 12729220 8 Anxiety
127292202 12729220 9 Candida infection
127292202 12729220 10 Prophylaxis
127292202 12729220 11 Prophylaxis
127292202 12729220 12 Antiemetic supportive care
127292202 12729220 13 Prophylaxis against gastrointestinal ulcer
127292202 12729220 14 Antiemetic supportive care
127292202 12729220 15 Thrombosis prophylaxis
127292202 12729220 16 Diabetes mellitus
127292202 12729220 17 Diabetes mellitus
127292202 12729220 18 Analgesic therapy
127292202 12729220 19 Mandibulofacial dysostosis
127292202 12729220 20 Sleep disorder
127292202 12729220 21 Antiviral prophylaxis
127292202 12729220 22 Antifungal prophylaxis
127292202 12729220 23 Hypocalcaemia
127292202 12729220 24 Delirium
127292202 12729220 25 Antiviral prophylaxis

Outcome of event

Event ID CASEID OUTC COD
127292202 12729220 OT
127292202 12729220 LT

Reactions reported

Event ID CASEID DRUG REC ACT PT
127292202 12729220 Acute kidney injury
127292202 12729220 Sepsis
127292202 12729220 Tumour lysis syndrome
127292202 12729220 Urinary retention

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
127292202 12729220 1 20160728 0
127292202 12729220 2 20160729 0
127292202 12729220 3 20160728 0
127292202 12729220 4 20160728 0
127292202 12729220 5 20160728 0
127292202 12729220 6 20160728 0
127292202 12729220 8 20160715 0
127292202 12729220 9 20160715 0
127292202 12729220 10 20160715 0
127292202 12729220 11 20160715 0
127292202 12729220 12 20160715 0
127292202 12729220 13 20160715 0
127292202 12729220 14 20160725 0
127292202 12729220 15 20160718 0
127292202 12729220 16 20160719 0
127292202 12729220 17 20160719 0
127292202 12729220 18 20160725 0
127292202 12729220 19 20160725 0
127292202 12729220 20 20160725 0
127292202 12729220 21 20160726 0
127292202 12729220 22 20160726 0
127292202 12729220 23 20160726 0
127292202 12729220 25 20160730 0